Sectoral Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Sectoral Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-142,510	Closed	-$2.89M	–	100
2023 Q4	$2.89M	Buy	+142,510	New	+$1.87M	1.24%	27
2023 Q2	–	Sell	-80,029	Closed	-$1.38M	–	124
2023 Q1	$1.38M	Buy	80,029 +26,193	+49%	+$509K	0.26%	88
2022 Q4	$1.2M	Buy	+53,836	New	+$832K	0.23%	93
2021 Q1	–	Sell	-5,224	Closed	-$217K	–	120
2020 Q4	$217K	Buy	+5,224	New	+$216K	0.02%	97

Other funds holding FDMT

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sectoral Asset Management's FDMT Position: Q1 2024 in Review

Sectoral Asset Management sold out of 4D Molecular Therapeutics (FDMT) in Q1 2024, closing a stake of 142,510 shares — an estimated $2.89M sold.

Sectoral Asset Management first reported a position in FDMT in Q4 2020 and held it in 4 quarters. The position peaked at $2.89M in Q4 2023. 147 funds tracked by Wall St. Rank hold FDMT as of Q1 2024.

Sectoral Asset Management reported no remaining 4D Molecular Therapeutics position as of Q1 2024 after selling out during the quarter.
Sectoral Asset Management sold 142,510 4D Molecular Therapeutics shares in Q1 2024, an estimated $2.89M.
Sectoral Asset Management first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 4 quarters.
Sectoral Asset Management's 4D Molecular Therapeutics position peaked at $2.89M in Q4 2023.
147 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2024.

Based on Sectoral Asset Management's 13F filing for Q1 2024, filed 14 May 2024.